Results from prospective trials show a “clear prognostic value” for CTC counts Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, announced today that results from a new study presented at the virtual 2020 meeting of the American Society of Clinical Oncology (ASCO) suggest that circulating tumor cell (CTC) counts may be useful in determining long-term prognosis …
Menarini Silicon Biosystems Develops New Assay Workflow for Circulating Multiple Myeloma Cells
Technology to Be Introduced at the Molecular Medicine Tri-Conference May Offer Alternative to Invasive Bone Marrow Biopsy for Monitoring Disease Progression Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, announced today that it will introduce a new semi-automated assay workflow utilizing the CELLSEARCH® and DEPArrayTM platforms to enumerate and characterize circulating multiple myeloma cells (CMMC) from peripheral blood samples.** …
New Studies Using CELLSEARCH Circulating Tumor Cell Test to be Featured at San Antonio Breast Cancer Symposium
Research Adds to Growing Evidence of Clinical Utility of CTCs for the management of Metastatic Breast Cancer Patients Menarini Silicon Biosystems announced today that new data utilizing the company’s CELLSEARCH® Circulating Tumor Cell Test will be presented at the upcoming 2018 San Antonio Breast Cancer Symposium (SABCS). A total of 21 studies will be presented: 20 posters and an oral …
Circulating Tumor Cells To Help Stage Metastatic Breast Cancer, New Research To Be Featured at ASCO Annual Meeting
Study adds to significant body of evidence supporting clinical utility of CELLSEARCH Bologna, Italy and Huntingdon Valley, Pa., MAY 30, 2018 — Menarini Silicon Biosystems announced today that a new study has found that using circulating tumor cells (CTCs), a form of liquid biopsy, holds promise as a key tool for developing a staging system that can have a significant impact in …